Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net – Burnie Online News
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Continue Reading
-
General12 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News18 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Noosa News23 hours agoResilience features in Sunshine Coast Open House
-
Business20 hours agoBell Potter names the best ASX shares to buy in October